257 related articles for article (PubMed ID: 10636461)
21. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
Semin Thromb Hemost; 1996; 22(3):255-9. PubMed ID: 8836010
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro.
Hauptmann J; Kaiser B
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):577-82. PubMed ID: 8218854
[TBL] [Abstract][Full Text] [Related]
23. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
[TBL] [Abstract][Full Text] [Related]
24. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
25. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
26. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
Nagashima H
J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
[TBL] [Abstract][Full Text] [Related]
27. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
28. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
[TBL] [Abstract][Full Text] [Related]
29. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
30. Influence of red algal sulfated polysaccharides on blood coagulation and platelets activation in vitro.
Sokolova EV; Byankina AO; Kalitnik AA; Kim YH; Bogdanovich LN; Solov'eva TF; Yermak IM
J Biomed Mater Res A; 2014 May; 102(5):1431-8. PubMed ID: 23765560
[TBL] [Abstract][Full Text] [Related]
31. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
33. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Nishida M; Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
J Cardiovasc Pharmacol; 2000 Dec; 36(6):770-5. PubMed ID: 11117378
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides.
Lee SH; Lee W; Bae JS; Ma E
Molecules; 2016 May; 21(5):. PubMed ID: 27213328
[TBL] [Abstract][Full Text] [Related]
35. Thrombin and factor Xa enhance neutrophil chemoattractant production after ischemia/reperfusion in the rat liver.
Yamaguchi Y; Okabe K; Liang J; Ohshiro H; Ishihara K; Uchino S; Zhang JL; Hidaka H; Yamada S; Ogawa M
J Surg Res; 2000 Jul; 92(1):96-102. PubMed ID: 10864488
[TBL] [Abstract][Full Text] [Related]
36. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Becker RC; Alexander J; Dyke CK; Harrington RA
Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
38. DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes.
Kumura T; Hino M; Yamane T; Tominaga K; Tatsumi N
Clin Chim Acta; 2000 Apr; 294(1-2):27-35. PubMed ID: 10727670
[TBL] [Abstract][Full Text] [Related]
39. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
40. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition.
Brandstetter H; Kühne A; Bode W; Huber R; von der Saal W; Wirthensohn K; Engh RA
J Biol Chem; 1996 Nov; 271(47):29988-92. PubMed ID: 8939944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
